Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 12 May 2026
Disease-free survival of 96% with no severe GVHD in acute leukemia, other blood cancers
Read Full NewsComplicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.
The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.
1.
Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease
2.
Psychedelic Therapy Tied to Reduced Depression, Anxiety.
3.
Pooled Cord Blood Transplants Achieve Near-Perfect Results in Early Trial
4.
Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity
5.
Young adults who are obese are at risk for 17 different types of cancer in the future.
1.
The Latest Research on Wiskott Aldrich Syndrome
2.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
3.
From Bench to Bedside: The New Era of Lymphoma Treatment and Education
4.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
5.
Introduction to Immune Thrombocytopenic Purpura
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
2.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
3.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge